Jazz Pharmaceuticals JAZZ Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's net income?
- Jazz Pharmaceuticals (JAZZ) reported net income of $293.1M in Q1 2026.
- How has Jazz Pharmaceuticals's net income changed year-over-year?
- Jazz Pharmaceuticals's net income increased by 416.9% year-over-year, from -$92.5M to $293.1M.
- What is the long-term trend for Jazz Pharmaceuticals's net income?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's net income has grown at a 19.3% compound annual growth rate (CAGR), from -$329.67M to $560.12M.
- What does net income mean?
- The total profit or loss a company earned during a period.
- How do you interpret net income?
- An increase indicates higher profitability, while a decrease suggests declining margins or rising costs.
- How does net income compare across companies?
- Standard across all public companies; peers in pharma often show volatility due to R&D cycles.